Kymriah

October 1, 2019October 1, 2019

Radiation Prior to CAR T-cell Therapy in Non-Hodgkin’s Lymphoma May Ease Side Effects, Study Suggests

News

Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the ... Read more

March 22, 2019March 22, 2019

Scotland Rejects NHS Access to Kymriah for Aggressive Diffuse Large B-cell Lymphoma

News

Scotland’s healthcare system has rejected the use of Novartis‘ immunotherapy Kymriah (tisagenlecleucel) for adults with aggressive diffuse large B-cell lymphoma (DLBCL) who failed at least two prior lines of therapy. The Scottish Medicines Consortium (SMC) ... Read more

February 8, 2019

U.K. Institute Recommends Kymriah for Adults with Aggressive DLBCL

News

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended that Kymriah (tisagenlecleucel) be offered to patients with difficult-to-treat diffuse large B-cell lymphoma (DLBCL) through the Cancer Drugs Fund. Specifically, this Novartis-developed therapy ... Read more

September 25, 2018

NICE Rejects Kymriah for England’s NHS to Treat Aggressive DLBCL

News

Kymriah (tisagenlecleucel), developed by Novartis, has not been recommended as a treatment for adults with aggressive diffuse large B-cell lymphoma (DLBCL) for England’s National Health Service (NHS). The National Institute for Health ... Read more

July 10, 2018

Lymphoma Therapies Kymriah, Yescarta Recommended for Approval in Europe

News

The European Medicines Agency (EMA) has recommended the approval of two lymphoma medications: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). The EMA’s decision represents the first two recommendations for chimeric antigen receptors ... Read more

June 25, 2018December 6, 2018

Kymriah Ellicits Prolonged Complete Responses in Advanced DLBCL Patients, Trial Data Show

News

Kymriah (tisagenlecleucel), a chimeric antigen receptor (CAR) T-cell therapy developed by Novartis, is able to ellicit prolonged complete responses with minor side effects in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according ... Read more

May 3, 2018

FDA Approves Kymriah for Relapsed or Refractory Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory large B-cell lymphoma, Novartis announced. Specifically, the approval of intravenous Kymriah suspension is ... Read more

March 29, 2018March 29, 2018

CAR T-cell Therapies Deemed Cost-effective for B-cell Cancers in New Report

News

Treatment with chimeric antigen receptor (CAR) T-cell therapies in B-cell cancers, like certain types of lymphoma and leukemia, is associated with an increase in quality-adjusted and overall survival compared to ... Read more

January 18, 2018January 18, 2018

FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis’ application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large ... Read more

December 22, 2017December 22, 2017

Benefits of 2 CAR T-cell Therapies May Justify Their High Price, ICER Report Argues

News

The clinical benefits of two recently approved CAR T-cell cancer therapies appear to justify their hefty price, a draft report by University of Colorado researchers suggests. The researchers — Melanie Whittington, ... Read more